PMID- 18052621
OWN - NLM
STAT- MEDLINE
DCOM- 20080317
LR  - 20191110
IS  - 1130-6343 (Print)
IS  - 1130-6343 (Linking)
VI  - 31
IP  - 4
DP  - 2007 Jul-Aug
TI  - [Observational study of the efficacy and tolerability of bosentan for the 
      treatment of pulmonary hypertension in a tertiary referral hospital].
PG  - 248-52
AB  - OBJECTIVE: The pathogenesis of pulmonary hypertension (PHT) involves elevated 
      levels of endothelin. Bosentan is a receptor antagonist used for the treatment of 
      this disease. The purpose of the study is to assess the efficacy and tolerability 
      of this drug in clinical practice. METHOD: A retrospective observational study of 
      10 patients with primary pulmonary hypertension (seven) and secondary to 
      pulmonary thromboembolism (PTE), treated with bosentan. The decrease in systolic 
      pulmonary artery pressure (SPAP) and the New York Heart Association (NYHA) 
      functional classification were measured, together with treatment safety based on 
      transaminase levels in the mid term and long term until the treatment period of 
      two years was completed. RESULTS: The decrease in SPAP between the beginning and 
      the end of the treatment was not significant. Three of the ten patients began 
      treatment in class II, five in class III and two in class IV. After 12 months of 
      treatment, six patients were in class II, two in class IV, one patient died and 
      another stopped the treatment due to toxicity. Four patients continued the 
      treatment for 24 months, and the results were compared with those obtained during 
      the first year: Two patients remained in class II, one patient deteriorated to 
      class III and the four died. CONCLUSIONS: Bosentan is shown to be effective after 
      six months of treatment, losing efficacy after two years. Bosentan gave 
      satisfactory results in PHT secondary to PTE.
FAU - Pellicer Franco, C
AU  - Pellicer Franco C
AD  - Servicio de Farmacia, Complejo Hospitalario de Pontevedra, C/Mourente s/n, 
      Pontevedra, Spain. consuelo.pellicer.franco@sergas.es
FAU - Iglesias Neiro, P
AU  - Iglesias Neiro P
FAU - Pineiro Corrales, G
AU  - Pineiro Corrales G
LA  - spa
PT  - Journal Article
TT  - Estudio observacional sobre la efectividad y tolerabilidad del bosentan en el 
      tratamiento de la hipertension pulmonar en un hospital general de tercer nivel.
PL  - Spain
TA  - Farm Hosp
JT  - Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad 
      Espanola de Farmacia Hospitalaria
JID - 9440679
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Sulfonamides)
RN  - Q326023R30 (Bosentan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Bosentan
MH  - Female
MH  - Hospitals, General
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sulfonamides/adverse effects/*therapeutic use
EDAT- 2007/12/07 09:00
MHDA- 2008/03/18 09:00
CRDT- 2007/12/07 09:00
PHST- 2007/12/07 09:00 [pubmed]
PHST- 2008/03/18 09:00 [medline]
PHST- 2007/12/07 09:00 [entrez]
AID - 10.1016/s1130-6343(07)75382-5 [doi]
PST - ppublish
SO  - Farm Hosp. 2007 Jul-Aug;31(4):248-52. doi: 10.1016/s1130-6343(07)75382-5.